The pharmaceutical industry is on a bit of a hot streak. Last Monday, Pfizer announced promising results for its coronavirus vaccine. Later that day, Eli Lilly received emergency-use authorization from the FDA for its antibody treatment, which may prevent COVID-19 from growing serious in patients who contract the coronavirus and are not yet hospitalized. Not to be outdone, Moderna released similarly positive results for its vaccine candidate yesterday.
Big Pharma’s Hot Streak — and What Could Stop It
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.